US2022105129A1PendingUtilityA1

Pharmaceutical compositions

Assignee: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTDPriority: Nov 16, 2007Filed: Dec 16, 2021Published: Apr 7, 2022
Est. expiryNov 16, 2027(~1.3 yrs left)· nominal 20-yr term from priority
A61K 47/26A61K 33/26A61K 9/2059A61K 47/02A61P 7/00A61P 3/00A61K 9/1635A61K 9/2866A61P 13/12A61K 9/1623A61K 9/0056A61K 9/009A61P 7/08A61K 9/2027A61P 5/18A61K 9/2018A61K 9/1652A61K 9/2095A61K 9/70A61K 9/205A61P 13/00A61P 19/08A61K 9/0053A61P 3/12
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Claims

exact text as granted — not AI-modified
1 - 25 . (canceled) 
     
     
         26 . A pharmaceutical composition comprising iron oxy-hydroxide, saccharose, starch, and at least one excipient,
 wherein the iron oxy-hydroxide is present in the amount of 10 to 80% (w/w) expressed relative to the total weight of the composition,   wherein the iron oxy-hydroxide is stabilized by at least saccharose and/or starch,   wherein the composition is in a form suitable for oral administration,   wherein the iron oxy-hydroxide is essentially non-bioabsorbable, and   wherein the total amount of iron oxy-hydroxide, saccharose, and starch is greater than about 50% (w/w) expressed relative to the total weight of the composition.   
     
     
         27 . The pharmaceutical composition according to  claim 26 , wherein the starch comprises native starch and pregelatinized starch. 
     
     
         28 . The pharmaceutical composition according to  claim 26 , wherein the dosage form has a disintegration rate in the range from 1 second to 3 minutes. 
     
     
         29 . The pharmaceutical composition according to  claim 27 , wherein the dosage form has a disintegration rate in the range from 1 second to 3 minutes. 
     
     
         30 . The pharmaceutical composition according to  claim 26 , wherein the dosage form is chosen from chewable pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         31 . The pharmaceutical composition according to  claim 27 , wherein the dosage form is chosen from chewable pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         32 . The pharmaceutical composition according to  claim 28 , wherein the dosage form is chosen from chewable pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         33 . The pharmaceutical composition according to  claim 29 , wherein the dosage form is chosen from chewable pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         34 . The pharmaceutical composition according to  claim 28 , wherein the dosage form is chosen from dry powders and wherein the disintegration rate is in the range from 1 second to 3 minutes. 
     
     
         35 . The pharmaceutical composition according to  claim 29 , wherein the dosage form is chosen from dry powders and wherein the disintegration rate is in the range from 1 second to 3 minutes. 
     
     
         36 . The pharmaceutical composition according to  claim 26 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         37 . The pharmaceutical composition according to  claim 27 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         38 . The pharmaceutical composition according to  claim 28 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         39 . The pharmaceutical composition according to  claim 29 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         40 . The pharmaceutical composition according to  claim 34 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         41 . The pharmaceutical composition according to  claim 35 , wherein the at least one excipient is chosen from modified starches and cross-linked polyvinylpyrrolidones. 
     
     
         42 . The pharmaceutical composition according to  claim 36 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         43 . The pharmaceutical composition according to  claim 37 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         44 . The pharmaceutical composition according to  claim 38 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         45 . The pharmaceutical composition according to  claim 39 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         46 . The pharmaceutical composition according to  claim 40 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         47 . The pharmaceutical composition according to  claim 41 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         48 . The pharmaceutical composition according to  claim 27 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         49 . The pharmaceutical composition according to  claim 29 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         50 . The pharmaceutical composition according to  claim 35 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         51 . The pharmaceutical composition according to  claim 39 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         52 . The pharmaceutical composition according to  claim 41 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         53 . The pharmaceutical composition according to  claim 45 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium. 
     
     
         54 . The pharmaceutical composition according to  claim 47 , further comprising at least one additional excipient chosen from starches, methylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, pregelatinized starch, clays, cellulose, powdered cellulose, pregelatinized starch, sodium alginate, alginic acid, guar gum, magnesium aluminum silicate, and polacrilin potassium.

Join the waitlist — get patent alerts

Track US2022105129A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.